Prior studies have shown that patients with anti-Ro52 and anti-Ro60 antibodies have higher rates of leukopenia and increased production of CXCL10, potentially contributing to a lowered vaccine efficacy in this subgroup (29). The gene discussed is CXCL10; the disease is Decreased total leukocyte count.